Pharmacokinetics of Enrofloxacin Following Intravenous and Intramuscular Administration in Kilis Goats

  • İbrahim AKTAŞ
  • Levent ALTINTAŞ
  • Erdim Ozan ÇAKIR
  • Onur DEMİR
  • Ender YARSAN
Keywords: Pharmacokinetics, Kilis goats, enrofloxacin, ciprofloxacin.

Abstract

Enrofloxacin (ENR) is a wide broad-spectrum antibacterial drug used widely in veterinary medicine. It was aimed to investigate the pharmacokinetic behavior of ENR in Kilis goats at single dosage of 2.5 mg/kg per goat body weight (bw) in the present study. A total of 10 healthy Kilis male goats were divided into 2 groups: each including 5 animals for the pharmacokinetic studies Group I, received 2.5 mg/kg via vena jugularis by IV route; Group 2 received the same dose by intramuscular route through administration at musculus semitendinosus at formulation. Group 1 blood samples were taken at 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8, 12, 18, 24, 36 and 48 hours and Group 2 blood samples were taken at 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8, 12, 18, 24, 36 and 48 hours after administration of drug. ENR and its metabolite, ciprofloxacin (CPR) analysis was performed by high-performance liquid chromatography. Maximal plasma concentration (Cmax 0.77 ± 0.05 μg/ml for IM) was reached at 1.00 h (Tmax) for IM. The elimination half-life (T1/2) of ENR was of 21.09 ± 0.87 h for IV and 29.75 ± 2.50 h for IM. The values of area under concentration-time curve (AUC) of ENR were of 6.46 ± 0.52 and 4.11 ± 0.35 μg.h/ml. ENR bioavailability (F) was calculated as 63.62%. The elimination half-life of CPR was of 19.31 ± 2.15 h for IV and 33.42 ± 1.28 h for IM.

Published
2019-09-19
Section
Articles